Catheter ablation for papillary muscle arrhythmias: A systematic review

Marco Valerio Mariani MD\textsuperscript{1} | Agostino Piro MD\textsuperscript{1} | Michele Magnocavallo MD\textsuperscript{1} | Cristina Chimenti MD\textsuperscript{1} | Domenico Della Rocca MD\textsuperscript{2} | Pasquale Santangeli MD\textsuperscript{3} | Andrea Natale MD\textsuperscript{2} | Francesco Fedele MD\textsuperscript{1} | Carlo Lavalle MD\textsuperscript{1}

\textsuperscript{1}Department of Cardiovascular, Respiratory, Nephrological, Anaesthesiological and Geriatric Sciences "Sapienza", University of Rome, Rome, Italy
\textsuperscript{2}St. David’s Medical Center, Texas Cardiac Arrhythmia Institute, Austin, Texas, USA
\textsuperscript{3}Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

Correspondence
Marco Valerio Mariani, MD, Department of Cardiovascular, Respiratory, Nephrological, Anaesthesiological and Geriatric Sciences "Sapienza" University of Rome, Viale del Policlinico 155, 00161, USA.
Email: marcoval.mariani@gmail.com

[Correction added on 11th May 2022, after first online publication: CRUI funding statement has been added.]

Abstract

Background: Catheter ablation of papillary muscle ventricular arrhythmias (PM-VAs) has been associated with unsatisfactory results. Features that may affect acute and long-term procedural outcomes are not well established.

Objective: To systematically review the available data in the literature assessing efficacy and safety of PM-VAs catheter ablation.

Methods: An online search of PubMed, Cochrane Registry, Web of Science, Scopus and EMBASE libraries (from inception to March 1, 2021) was performed, in addition to manual screening. Twenty-one observational noncontrolled case-series were considered eligible for the systematic review, including 536 patients.

Results: Postero-medial PM harbored 60.8% of PM-VAs, while antero-lateral PM and right ventricular PMs 34.9% and 4.3% of cases, respectively. The mean acute success rate of the index ablation procedure was 88.1% (95% CI 82.8% to 91.9%, \( p < .001 \), \( \text{i}^2 = 0\% \)). After a mean follow-up period of 15.5 ± 17.4 months, pooled long-term arrhythmia-free rate was 69.2%, while the pooled long-term success rate after multiple ablation procedure was 84.9%. Overall, procedure complications occurred in nine patients (1.7%) and no procedure-related deaths were reported. The use of intracardiac echocardiography (ICE) as well as contact force sensing (CFS) and irrigated catheters during ablation was associated with higher rates of arrhythmia-freedom at long-term follow-up.

Conclusions: Catheter ablation is an effective and safe strategy for PM-VAs, with an acute success rate of 88.1%, a long-term success rate of 69.2%, with a relatively low procedural complication rate. The use of ICE, irrigated catheters and catheters with CFS capability was associated with higher rates of arrhythmia-freedom at long-term follow-up.

KEYWORDS
intracardiac echocardiography, irrigated ablation catheters, papillary muscle, ventricular arrhythmias
INTRODUCTION

Ventricular arrhythmias (VAs), such as premature ventricular contractions (PVCs) or ventricular tachycardia (VT), can originate from different structures inside the ventricles.\(^1\) Papillary muscles (PMs) have become increasingly recognized as a possible site of origin of arrhythmias with typical electrocardiographic features (Figure 1), both in patients with and without structural heart disease (SHD), representing the site of origin of almost 5% of all idiopathic PVCs referred for ablation.\(^2\) Catheter ablation is an effective and safe therapeutic strategy for VAs, with success rate as high as 93% for arrhythmias originating from right ventricular outflow tract (RVOT).\(^3\) However, catheter ablation of PM-VAs has historically been associated with lower acute success rates (80%) and unsatisfactory long-term results (60% out of antiarrhythmic drugs), mainly due to the complex anatomy, the variable location of the ventricular arrhythmia site of origin and changing exits during ablation linked to anisotropic conduction.\(^3\)–\(^5\) During the past years, small studies have reported the outcomes of PM-VAs ablation using different catheter technologies, energy sources and preprocedural and intraprocedural imaging modalities. In this report, we aimed to systematically review the available data in the literature and assess the efficacy and periprocedural complication rates following catheter ablation for PM-VAs.

METHODS

2.1 Search strategy, selection criteria and outcomes

The present systematic review was performed according to Cochrane Collaboration and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.\(^6\) This study was approved by the Institutional Review Boards on Human Research.

An online search of PubMed, Cochrane Registry, Web of Science, Scopus and EMBASE libraries (from inception to March 1, 2021) was performed, in addition to manual screening. We used the following keywords: ([papillary muscle]) AND ([ablation] OR [catheter ablation] OR [cryoablation] OR [radiofrequency ablation]) AND ([VAs] OR [VT] OR [premature ventricular contraction] OR [PVC]). No language restriction was applied. Reviews, editorials, letters, meta-analysis, case reports, and abstracts were excluded.

The systematic review included studies on patients undergoing catheter ablation of papillary muscle arrhythmias. In the absence of a control group, a non-controlled observational analysis was performed. To be considered eligible, observational non-controlled case series required at least five patients. The efficacy outcomes were acute termination of PM arrhythmias and long-term freedom from PM arrhyth-
mias after catheter ablation procedure. The safety outcomes included peri-operative mortality and procedure-related complications. Eligibility criteria required studies to provide patients’ demographics and acute success rate of catheter ablation.

Two independent reviewers (M.V.M. and A.P.) screened all abstracts and titles to identify potentially eligible studies, of which full text was subsequently interrogated. Agreement of the two reviewers was required for eligibility of studies for analysis. Disagreements regarding the inclusion or the classification of a study were solved by a third reviewer (C.L.).

2.2 Data extraction and quality assessment

Data extraction was performed by two reviewers (M.V.M. and A.P.). Where available, for each study the following data were collected: first author and year of publication, study design, number of patients, demographic data (age and sex), left ventricular ejection fraction (LVEF), presence of cardiomyopathy, site of origin of the arrhythmias (anterolateral PM, posteromedial PM or right ventricular PMs), procedural data (type of catheter, energy, procedural and fluoroscopy time), follow-up duration, acute and long-term success rates, procedural mortality and procedure-related complications.

Study quality was formally evaluated by two reviewers (M.V.M. and A.P.) using the National Heart, Lung, and Blood Institute Quality Assessment Tool for Case Series Studies. The final classification of the studies required the agreement of both reviewers and any case of disagreement was solved by a third reviewer (C.L.).

2.3 Statistical analysis

Descriptive statistics are presented as means and standard deviations (SD) for continuous variables normally distributed and median and 25/75 interquartile for continuous variables non-normally distributed, or number of cases (n) and as percentages (%) for dichotomous and categorical variables. Statistical analysis was performed using Comprehensive Meta-Analysis Software (Version 2), starting by events and simple size for each included study. The effect size assessed was prevalence of acute termination of PM arrhythmias and long-term freedom from PM arrhythmias after catheter ablation procedure. Overall prevalence and 95% confidence interval were estimated. Statistical heterogeneity on each outcome of interest was quantified using $I^2$ statistic. Values of $I^2$ statistic, ≤25%, 50%, and ≥75% indicated low, moderate, and high heterogeneity, respectively, whereas for Q statistic, substantial heterogeneity was defined as a $p < .1$. Data were pooled using a fixed-effect model, whereas a random-effect model was preferred if moderate heterogeneity among studies was found. In addition, we also performed subgroup analyses based on catheter technology used (contact force sensing [CFS] vs. no CFS, irrigated vs. non-irrigated catheters), the use of imaging to assist ablation (ICE vs. no-ICE), cardiomyopathy (idiopathic arrhythmias vs. arrhythmias in SHD).

3 RESULTS

3.1 Study selection and patient characteristics

As shown in Figure 2, among 237 papers, 27 studies met the inclusion criteria. Subsequently, six studies were excluded because including duplicate patients. Hence, 21 studies were included in final analysis (16 single center studies and five multicenter studies), with a total population of 536 patients undergone catheter ablation of PM arrhythmias (Table 1). The mean age of the patients was 56.6 ± 16.3 years (female n = 191, 35.6%) and the mean LVEF was 47.8% ± 13.7%. Almost half of the patients (n = 244, 45.5%) presented cardiomyopathy at the time of ablation, whereas 6 studies included only patients with idiopathic arrhythmias, without SHD. Cardiomyopathy was defined as any SHD, including ischemic heart disease (IHD), valvular heart disease (VHD) such as mitral valve prolapse (MVP) and dilated cardiomyopathy. The most common clinical arrhythmia was PVC, reported in 357 patients (67% of cases), while VT arising from PM was the only presenting arrhythmia in one study. Nine studies (42.8%) reported the mean PVC burden before ablation with an overall burden of 21.1% ± 14.7%. In the 12 studies reporting data on previous antiarrhythmic drug treatment, most patient undergone ablation after failure of at least one antiarrhythmic medication. Using the National Heart, Lung and Blood Institute Quality Assessment Tool for Case Series Studies, all the studies included in the analysis were observational case series, without control group. Six studies were prospective reports, and 15 studies had a retrospective design. Using the National Heart, Lung and Blood Institute Quality Assessment Tool for Case Series Studies, 16 studies fulfilled eight criteria, four studies fulfilled seven criteria, and one study fulfilled six criteria.

3.2 Procedural data

PM arrhythmias were frequent or inducible during all the procedure. Overall, 554 PM were targeted, 355 posteromedial PM, 204 anterolateral PM and 25 right ventricular (RV) PM (4.3% of all PMVs included). As shown in Table 2, 11 studies (52.3%) reported the procedure duration time (mean 212.7 ± 104.2 min) and eight studies reported fluoroscopy time (mean 19.4 ± 17.8 min). Intracardiac echocardiography (ICE) was used to guide mapping and ablation in 19 studies (86.4%). In 13 studies ICE assisted all procedures, whereas in six studies only a portion of the procedure was ICE-guided. Three dimensional electroanatomical mapping system assisted the procedure in all cases. A combination of Biosense Webster CARTO system in 16 studies and Abbott-St. Jude
Ensite NavX in four studies,\(^{15,18,29,32}\) a combination Biosense Webster CARTO system and Boston Scientific Rhythmia in one paper\(^{13}\). In four studies,\(^{19–20,22,28}\) both robotic magnetic navigation-guided (RMN) ablation and manual ablation were used, combining the Stereotaxis Niobe ES magnetic navigation system (Stereotaxis, St. Louis, MO, USA) to CARTO mapping system. Access to the left ventricle was obtained through retrograde crossing the aortic valve in six studies\(^{13–14,17–18,24,27}\) or trans-septal puncture in two studies.\(^{19–20}\) In 10 studies both the approaches were used,\(^{15,23,25–26,28–33}\) and in three studies the approach used for mapping and ablating the PM-VAs was not reported.\(^{16,21–22}\) Mapping and ablation catheters features were reported in 95% of the studies (n = 20, Table 2). Irrigated catheters were used in 11 studies,\(^{13,16,19–20,22–23,25–27,30–33}\) whereas in nine reports the procedure was performed using a combination of irrigated or nonirrigated.\(^{14,17–18,21,24,28–29}\) A combination of catheters with and without CFS capabilities were used in seven studies,\(^{26–28,30–31}\) whereas in 13 studies ablation was performed with catheters without CFS capabilities.\(^{13–25}\) During activation mapping, the mean pre-QRS activation time was 29.6 ± 10.9 ms (Table 2). The discrete ablation site was reported in 38.1% of cases (eight studies,\(^{13–14,18,20,25–26,32–33}\) 272 ablation procedures), and was mainly located at the base of the PM (115 cases, 42.3%), at PM tip (88 cases, 32.3%), at PM body (50 cases, 18.4%). In the last 19 ablation procedures (7%), the entire PM was targeted to successfully eliminate PM arrhythmias.\(^{33}\) At successful ablation site, 15 studies (71.4%) reported the presence or absence of Purkinje-like potentials.\(^{14,16–25,29–32}\) These potentials were recorded in 13 studies,\(^{16–25,29,31–32}\) with a prevalence ranging from 22% to 67% and a total prevalence of 34.5% (108/313 procedures). A combination of radiofrequency and cryoenergy was used for ablation in three studies.\(^{16,32–33}\) Radiofrequency application time was reported in 10 studies (47.6%),\(^{16,18–21,25–26,29,31,33}\) with an overall mean radiofrequency time of 21 ± 19.1 min. For most of the studies, the acute ablation endpoint was the complete elimination and/or non-inducibility of PM arrhythmias with burst pacing or isoproterenol infusion.

### 3.3 Procedural outcomes: efficacy and safety of catheter ablation

The mean acute success rate of the index ablation procedure was 88.1% (95% CI 82.8% to 91.9%, \(p < .001, \text{i}^2\) 0%) (Figure 3), with 10
## TABLE 1  Baseline characteristics of the included studies

| Study                        | Year | Centres | Design  | Number of patients | Age (years) | Female (n;%) | Mean LVEF | Cardiomyopathy | PVC burden | Previous AADs failed | Quality |
|------------------------------|------|---------|---------|-------------------|-------------|--------------|-----------|-----------------|------------|----------------------|---------|
| Doppalapudi et al. 13        | 2008 | Single center | Prospective | 7                  | 57.1 ± 15.1 | 2 (29%)      | N.A.      | N.A.            | N.A.       | N.A.                 | 7       |
| Yamada et al. 14             | 2009 | Single center | Prospective | 6                  | 62 ± 15      | 3 (50%)      | 60        | 0 (0%)          | N.A.       | Yes                  | 8       |
| Abouezzedine et al. 15       | 2010 | Single center | Retrospective | 5                  | 69 ± 133     | 1 (20%)      | 41 ± 24   | 5 (100%)        | N.A.       | Yes                  | 7       |
| Yokokawa et al. 16           | 2010 | Single center | Retrospective | 40                 | 51 ± 14      | 25 (62.5%)   | 46 ± 13   | 20 (50%)        | 15.1 ± 12.9 | N.A.                | 8       |
| Yamada et al. 17             | 2010 | Single center | Prospective | 19                 | 59 ± 14      | 6 (32%)      | 63 ± 6    | 0 (0%)          | N.A.       | N.A.                 | 7       |
| Ban et al. 18                | 2013 | Single center | Retrospective | 12                 | 52 ± 9       | 7 (58%)      | 53 ± 9    | 0 (0%)          | N.A.       | Yes                  | 8       |
| Santoro et al. 19            | 2014 | Multicenter | Prospective | 6                  | 40 ± 11      | 4 (66.7%)    | 56.3 ± 9  | 1 (17%)         | 20.5 ± 9.3 | Yes                  | 8       |
| Santoro et al. 20            | 2014 | Single center | Retrospective | 8                  | 42 ± 13      | 6 (75%)      | 60 ± 4    | 0 (0%)          | 14 ± 3     | Yes                  | 8       |
| Van Herendael et al. 21      | 2014 | Multicenter | Retrospective | 8                  | 56 ± 15      | 0 (0%)       | N.A.      | 6 (75%)         | N.A.       | 8 (100%)             | 8       |
| Al’Aref et al. 22            | 2015 | Single center | Retrospective | 18                 | 68 ± 10      | 5 (28%)      | N.A.      | 14 (78%)        | N.A.       | 2 (11%)              | 8       |
| Chang et al. 23              | 2016 | Single center | Prospective | 13                 | 40.2 ± 13.8  | 5 (38%)      | 58 ± 4    | 0 (0%)          | 11.6 ± 10.8 | N.A.               | 8       |
| Wo et al. 24                 | 2016 | Single center | Retrospective | 16                 | 47 ± 13      | 5 (31%)      | 59 ± 12   | 2 (12.5%)       | N.A.       | N.A.                | 8       |
| Peichl et al. 25             | 2017 | Multicenter | Retrospective | 34                 | 62 ± 12      | 11 (32%)     | 50 ± 9    | 7 (21%)         | 22 ± 10    | N.A.                | 8       |
| Proietti et al. 26           | 2017 | Multicenter | Retrospective | 16                 | 67 ± 6       | 5 (31%)      | 40.1 ± 11 | 10 (63%)        | N.A.       | Yes                  | 8       |
| Lee et al. 27                | 2018 | Single center | Retrospective | 23                 | 52 ± 19.6    | 7 (30%)      | 47 ± 12   | 12 (52%)        | 25.3 ± 17.5 | Yes                | 8       |
| Bassil et al. 28             | 2018 | Single center | Retrospective | 35                 | 65 ± 12      | 11 (31%)     | 43 ± 13   | 12 (34)         | 16 ± 21    | N.A.                | 8       |
| Li et al. 29                 | 2018 | Multicenter | Retrospective | 21                 | 418 ± 16.4   | 7 (34%)      | N.A.      | 0 (0%)          | N.A.       | N.A.                | 6       |
| Itoh et al. 30               | 2018 | Single center | Retrospective | 34                 | 56 ± 18      | 16 (47%)     | N.A.      | 15 (44%)        | N.A.       | Yes                  | 8       |
| Enriquez et al. 31           | 2019 | Single center | Retrospective | 25                 | 547 ± 15.7   | 16 (64%)     | 50.5 ± 11.8 | 25 (100%)    | 24.4 ± 13.1 | 23 (92%)             | 7       |
| Rivera et al. 32             | 2019 | Single center | Retrospective | 53                 | 49 ± 17      | 18 (34%)     | 53 ± 11   | 30 (57%)        | N.A.       | Yes                  | 8       |
| Lin et al. 33                | 2020 | Single center | Retrospective | 137                | 62 ± 15      | 31 (23%)     | 42.0 ± 14.5 | 83 (61%)     | 24 ± 14     | N.A.                | 8       |
| **Total**                    |      |          |         | **536**            | **56.6 ± 16.3** | **191 (35.6%)** | **47.8 ± 13.7** | **244 (45.5%)** | **21.1 ± 14.7%** |          |

Abbreviations: AADs: antiarrhythmic drugs; LVEF: left ventricular ejection fraction; N.A: not available; PVC: premature ventricular contraction.
**TABLE 2**  Procedural characteristics

| Study                        | PM                  | Mapping system % (n) | ICE   | ICE          | Energy source  | CFS | RF or Cryo application time (min) | Procedural time (min) | Fluoroscopy time (min) | Approach | PLPs | Ablation site | Pre-QRS activation time (ms) |
|------------------------------|---------------------|----------------------|-------|--------------|----------------|-----|----------------------------------|-----------------------|------------------------|----------|------|---------------|--------------------------------|
| Doppalapudi et al. 13        | LVPM 7              | Carto/Rhythmia       | No    | Irrigated    | RF             | No  | N.A.                             | N.A.                  | N.A.                   | TA       | N.A. | 100% base     | 29 ± 2                                         |
| Yamada et al. 14             | LVAL 6              | Carto                | Yes (66%) | Both         | RF             | No  | N.A.                             | N.A.                  | N.A.                   | TA       | 0(0) | 3 base, 3 middle | 27 ± 7                                         |
| Abouezeddine et al. 15       | LVPM 3, LVAL 2      | Carto-NavX           | Yes   | RF           | No             | N.A. | 24.5 ± 13.8                      | 16 ± 16               | 367 ± 141              | 57.3 ± 30 | N.A. | 0 (0)         | 253 ± 62.5                                     |
| Yokokawa et al. 16           | LVPM 21, LVAL 13, RV 8 | Carto               | Yes   | Irrigated Cryo* | No            | N.A. | 323.5 ± 100 N.A.                | N.A.                  | TA 8 (42%)             | N.A.     | 42 ± 12.5 | 37.5%          | 30.3 ± 16.1                                    |
| Yamada et al. 17             | LVPM 12, LVAL 7     | Carto                | Yes (68%) | Both         | RF             | No  | N.A.                             | N.A.                  | N.A.                   | TA 4 (42%) | N.A. | 27 ± 7.3      |                                              |
| Ban et al. 18                | LVPM 10, LVAL 2     | EnSite-NavX (17%)    | Yes (42%) | Both         | RF             | No  | N.A.                             | N.A.                  | N.A.                   | TA 4 (33%) | N.A. | 35 ± 11       |                                              |
| Santoro et al. 19            | LVPM 2, RVPL 4      | Carto/Stereotaxis    | Yes   | Irrigated    | RF             | No  | 19 ± 12                          | 367 ± 141             | 57.3 ± 30              | TS 4 (66.7%) | N.A. | 42 ± 12       |                                              |
| Santoro et al. 20            | RV septal PM 8      | Carto/Stereotaxis    | Yes (25%) | Both         | RF             | No  | 10.3 ± 3                         | 76.3 ± 27.5           | 36.4 ± 11.3            | TS 2 (25%) | N.A. | 28.3 ± 4.8    |                                              |
| Van Herendael et al. 21      | LVPM 6, LVAL 1, RV posterior PM 1 | Carto         | Yes   | Both         | RF             | No  | 26 ± 15                          | N.A.                  | N.A.                   | N.A. 5 (63%) | N.A. | 49 ± 15       |                                              |
| Al'Aref et al. 22            | LVPM 9, LVAL 9      | Carto/Stereotaxis    | Yes   | Irrigated    | RF             | No  | N.A.                             | N.A.                  | N.A.                   | N.A. 4 (22%) | N.A. | 23 ± 6        |                                              |
| Chang et al. 23              | LVPM 8, LVAL 5      | Carto                | Yes   | Irrigated    | RF             | No  | N.A.                             | N.A.                  | N.A.                   | Both 4 (31%) | N.A. | 37.2 ± 13.0  |                                              |
| Wo et al. 24                 | LVPM 8, LVAL 8      | Carto                | No    | Both         | RF             | No  | N.A.                             | N.A.                  | N.A.                   | TA 7 (44%) | N.A. | 38 ± 7        |                                              |
| Peichl et al. 25             | LVPM 19, LVAL 12, both 3 | Carto              | Yes   | Irrigated    | RF             | No  | 12.5 ± 8.7                       | 162 ± 63              | N.A.                   | TA 21, TS 10, both 3 | 10 (28%) | 67% tip, 19% mid, 14% base | 31 ± 9                                         |
| Proietti et al. 26           | LVPM 21, LVAL 7     | Carto                | Yes (63%) | Both         | RF             | No  | 7.9 ± 3.6                        | 213 ± 65              | 25 ± 15                 | TA 15, TS 9 | N.A. | 13 base, 13 middle, 2 tip | 35 ± 5                                         |
| Lee et al. 27                | LVPM 11, LVAL 6, both | Carto              | Yes (83%) | Both         | RF             | No  | 230 ± 62                         | 17 ± 16.5             | TA 22                | N.A. 22 ± 18 | N.A. | 22 ± 18       |                                              |
### TABLE 2 (Continued)

| Study          | PM                  | Mapping system % (n) | ICE | Catheters | Energy source | Energy source | CFS | RF or Cryo application time (min) | Procedural time (min) | Fluoroscopy time (min) | Approach | PLPs | Ablation site | Pre-QRS activation time (ms) |
|----------------|---------------------|----------------------|-----|-----------|---------------|---------------|-----|---------------------------------|----------------------|------------------------|----------|-----|---------------|-----------------------------|
| Bassil et al. 28 | LVPM 14, LVAL 20, RVPM 4 | Carto/stereotaxis 69% | Yes | Both      | RF            | Both (11.4%)  | N.A.| N.A.                            | 12.2 ± 20.5          | 6 TA, 29 TS            | N.A.    | N.A.|              | 27.7 ± 7.9                   |
| Li et al. 29    | LVPM 21             | Carto-NavX           | Yes | Both      | RF            | N.A.          | 13.8 ± 2.8 | 63.1 ± 16.2                    | N.A.                | Both 5                 | 6 (29%) | N.A.|              | 27.2 ± 8.4                   |
| Itoh et al. 30  | LVPM 20, LVAL 8, both 6 | Carto                | Yes | Irrigated | RF            | N.A.          | N.A. | 14.4 ± 4.4                      | Both                | 0 (0%)                | N.A.    | N.A.|              | 22 ± 8                      |
| Enriquez et al. 31 | LVPM 14, LVAL 8, 3 Both | Carto                | Yes | Irrigated | RF            | Both          | 35 ± 31 | 271 ± 81                       | 34 ± 22              | 21 TA, 4 TS             | 7 (28%) | N.A.|              | 30.6 ± 8.1                   |
| Rivera et al. 32 | LVPM 45, LVAL 8     | Carto-EnSite         | Yes (26%) | Irrigated | RF/Cryo      | Both (26%)   | N.A. | 144.4 ± 44.4                    | 10.7 ± 5             | Both                   | 32 (60%) | Base 63%; body 25%; apex 12% | 32 ± 8.1                   |
| Lin et al. 33   | LVPM 73, LVAL 51, both 13 | Carto                | Yes | Irrigated | RF/Cryo      | Both (71%)   | 23 ± 21 | 235 ± 92                      | 19 ± 15              | Both                   | N.A.    | 41% tip, 10% body, 35% base, 14% entire LV PAP muscle | 29 ± 9.6                   |
| Total           | LVPM 355 - LVAL 204 - RVPM 25 | 100%                 | 19/21 | 11 irrigate/9 both | 18 RF/3     | 13 no | CFS/7 CFS | 21 ± 19.1 | 2127 ± 104.2 | 19.4 ± 17.8 | 6 TA, 2 TS, 10 both | 13/15 (87%) | 115 base, 50 body, 88 tip, 19 entire PM | 29.6 ± 10.9               |

Abbreviations: CFS, contact force sensing; ICE, intracardiac echocardiography; LVAL, left ventricular antero-lateral; LVPM, left ventricular postero-medial; NA, not available; PLP, Purkinje-like potential; PM, papillary muscle; RF, radiofrequency; RVPM, right ventricular papillary muscle; TA, transaortic; TS, trans-septal.
studies reporting an acute success of 100% (Table 3). Data on long-term success after the index procedure, defined as absence of PM arrhythmia recurrences, were available for 14 studies. During a mean follow-up period of 15.5 ± 17.4 months, 282 patients remained free from arrhythmia recurrences with pooled long-term arrhythmia-free rate of 69.2% (95% CI 60.5% to 76.6%, p < .001, I² 23%) (Figure 4), while in 100 patients PM arrhythmias relapsed (Table 3). After the index procedure, 67 (12.5%) patients repeated procedures for recurrences and the long-term results after repeat ablation was available for eight studies. As shown in Figure 5, the pooled long-term success rate after multiple ablation procedure was 84.9% (95% CI 78.2% to 89.8%, p < .001, I² 0%). Only 4 out 5 studies including RVPM VAs ablation reported the acute procedural outcome of catheter ablation, whereas the study by Bassist et al. did not report the acute success rate for RVPM VAs ablation. Ablation was acutely successful in eliminating RVPM VAs in 100% of cases (21 patients), and only the study by Santoro et al. reported the long-term success rate of RVPM VAs ablation (100%).

No procedure-related deaths were reported (Table 3). Eighteen studies reported absence of any procedural complications. Overall, procedure complications occurred in nine patients (1.7%). Lee et al. reported one arteriovenous fistula in 23 patients (4.3%). Rivera et al. described three complications related to PM arrhythmia ablation in 53 patients: one cardiac tamponade related to transeptal puncture and two minor complications (details not reported). Eventually, Lin et al. reported an overall complication rate of 3.6% (n = 5) in 137 patients undergone PM ablation, including one acute aortic dissection related to cryo-catheter manipulation, two pericardial effusions requiring pericardiocentesis, one femoral pseudoaneurysm and one groin hematoma.

### 3.4 Subgroup analyses

Acute success rate was lower in studies reporting ablation of PM arrhythmias related to cardiomyopathy (86.4%, 95% CI 79.7% to 91.1%, p < .001, I² 0%) than in studies not including patients with cardiomyopathy (95.1%, 95% CI 87.6 to 98.1%, p < .001, I² 0%). Similar pooled acute success rates were found when analyzing studies reporting all ICE-guided procedures versus studies reporting only a portion of ICE-guided procedures or not using ICE at all (86.9% vs. 90.1%, respectively), the use of irrigated and non-irrigated catheters (87% vs. 91.1% respectively) and the use of CFS and non-CFS catheters (87.6% vs. 83.8% respectively). Targeting arrhythmia exit sites was associated with numerically higher acute success rate (94.5%), although this approach was related to poorer outcome at long-term follow-up (72.3%). The use of an ICE-guided approach was related to numerically larger success rate at long-term follow-up compared to not using ICE (74.2%, 95% CI 65.5% to 81.3%, p < .001, I² 0% vs. 61.2%, 95% CI 45.8% to 74.6%, p = .153, I² 18%, respectively). At long-term follow-up, success rates were numerically lower when ablation was performed with nonirrigated versus irrigated catheters (58.7%, 95% CI 41.5% to 74%, p = .32, I² 34% vs. 75%, 95% CI 68.8% to 80.3%, p < .001, I² 0%), and when using non-CFS versus CFS catheters (66.4%, 95% CI 54.3% to 76.7%, p = .009, I² 0% vs. 74.8%, 95% CI 61.4% to 84.7%, p = .001, I² 0%). The results of subgroup analyses are shown in Table 4.
TABLE 3 Procedural outcomes

| Study                        | Follow-up duration (months) | Acute success rate (%;N) | LT senza redo | Long-term success rate (%;N) | Procedural complications (%;N) | Procedural Mortality (%;N) | Redo Procedure |
|------------------------------|-----------------------------|--------------------------|---------------|-----------------------------|-------------------------------|---------------------------|-----------------|
| Doppalapudi et al.           | 8.9 ± 5.3                   | 100% (7)                 | 100% (7)      | 100% (7)                    | 0                             | 0                         | 0               |
| Yamada et al.                | 7 ± 4                       | 100% (6)                 | 33% (2)       | 67% (4)                     | 0                             | 0                         | 2 (33%)         |
| Abouezzeddine et al.         | N.A.                        | 100% (5)                 | N.A.          | N.A.                        | 0                             | 0                         | 0               |
| Yokokawa et al.              | 32 ± 20                     | 78% (31)                 | N.A.          | N.A.                        | 0                             | 0                         | 6 (15%)         |
| Ban et al.                   | 12 ± 9                      | 100% (12)                | 67% (8)       | 75% (9)                     | 0                             | 0                         | 1 (8%)          |
| Santoro et al.               | 58 ± 11                     | 100% (6)                 | 100% (6)      | 100% (6)                    | 0                             | 0                         | 0               |
| Van Herendael et al.         | 13.9 ± 24                   | 100% (8)                 | 62% (5)       | 62% (5)                     | 0                             | 0                         | 0               |
| Al'Aref et al.               | 7.3 ± 26.8                  | 83% (15)                 | N.A.          | N.A.                        | 0                             | 0                         | N.A.            |
| Chang et al.                 | 12.2 ± 6.9                  | 100% (13)                | 69.2% (9)     | 92.3% (12)                  | 0                             | 0                         | 3 (23%)         |
| Wo et al.                    | 20 ± 12                     | 100% (16)                | 100% (16)     | 100% (16)                   | 0                             | 0                         | 0 (0%)          |
| Peichl et al.                | 13 ± 16                     | 74% (25)                 | 71% (24)      | NA                          | 0                             | 0                         | 4 (12%)         |
| Proietti et al.              | 10.5 ± 7                    | 96% (15)                 | 62.5% (10)    | 87.5% (14)                  | 0                             | 0                         | 7 (44%)         |
| Lee et al.                   | 24                          | 72% (17)                 | N.A.          | N.A.                        | 1 (4.3%) fistola AV            | 0                         | 0               |
| Bassil et al.                | 2.7 ± 11.4                  | 73.5% (26)               | N.A.          | N.A.                        | 0                             | 0                         | 1               |
| Li et al.                    | 5–70                        | 95.2% (20)               | 60% (13)      | 90.5% (19)                  | 0                             | 0                         | 8 (38%)         |
| Itoh et al.                  | 16 ± 16                     | 100% (34)                | 71% (24)      | 76% (26)                    | 0                             | 0                         | 4 (11.7%)       |
| Enriquez et al.              | 31.5 ± 15.1                 | 78% (20)                 | N.A.          | N.A.                        | 0                             | 0                         | 5 (20%)         |
| Rivera et al.                | 13.2 ± 12.3                 | 92% (49)                 | 72% (38)      | N.A.                        | 3 (5.6%), one cardiac tamponade related to transeptal puncture | 0                         | 0 (0%)          |
| Lin et al.                   | 14.4 ± 15.9                 | 95% (130)                | 82% (112)     | 91% (125)                   | 5 (3.6%), one acute aortic dissection, two pericardial effusions requiring pericardiocentesis, one femoral pseudoaneurysm, one groin hematoma | 0                         | 15 (11%)        |
| Total                        | 15.5 ± 17.4                 | 88.1% (485)              | 69.2% (282)   | 84.9% (259)                 | 9/536 (1.7%)                  | 0 (0)                     | 67 (12.5%)      |

Abbreviations: AV, arteriovenous fistula; LT, long-term; N.A, not available.

4 | DISCUSSION

To our knowledge, this is the first systematic review on the ablation of PM-VAs. The major findings of this study are as follows: catheter ablation of PM-VAs is more effective and safer than previously thought, with high acute success rate that decreases at long-term follow-up; the presence of cardiomyopathy, including MVP, reduces the acute procedural success rate; the use of ICE-guided approach, as well as irrigated and CFS catheters are associated with higher rates of arrhythmia-free survival at long-term follow-up.

This systematic review shows that ablation of PM VAs has success rates as high as 88.1%, with low complication rate (1.7%). Generally, the outcomes related to the ablation of PM VAs, both in presence and absence of cardiomyopathy, have been poor, due to the complex anatomy, the variable location of the ventricular arrhythmia site of origin and changing exits during ablation linked to anisotropic conduction. In a retrospective multicenter analysis of the outcomes of idiopathic PVC ablation, acute procedural success was achieved in 80% of ablations, but PM arrhythmia origin was associated with the lowest long-term success rate (60%) when compared to RVOT, aortic cusps and epicardial arrhythmias. Moreover, PM ablation was associated with the longest procedural time, the larger amounts of radiofrequency energy and high rate of repeat ablation procedures (36%). These findings have led to recommend catheter ablation for PM-VAs as second-line therapy, if antiarrhythmic medications failed, are not tolerated or not the patient’s choice. In line with previous studies, we report a long-term outcome of PM-VAs ablation after single procedure as high as 69.2%, and an overall freedom rate from PM-VAs after repeated abla-
tion of 84.9%. However, our analyses suggest that some procedural and patient characteristics may be associated with better acute and/or long-term outcomes. Although PM-VAs are often idiopathic, the presence of cardiomyopathy has been associated with PM arrhythmogenicity; in particular, recent reports have shown that mitral valve prolapse (MVP) is associated with PM-VAs in more than 25% of patients undergoing ablation.27,31 In the absence of SHD, PM-VAs have a focal origin due to triggered activity or abnormal automaticity, whereas more complex reentrant arrhythmias are common in the presence of scar tissue. Acute success rate for catheter ablation of PM-VAs is lower in patients with cardiomyopathy (86.4%) than without SHD (95.1%), probably reflecting a more complex arrhythmic substrate.

Defining the anatomy and maintaining consistent catheter contact and stability during radiofrequency catheter deliveries are pivotal to suppress arrhythogenic focus and definitely eliminate PM-VAs. However, PMs are thick and highly contractile intracavitary structures, with multiple surfaces, and the creation of durable lesions of adequate size and deepness is challenging, addressing the high rate of recurrences at long-term follow-up. Piogetti et al26 showed that the use of a three-dimensional ICE-guided electroanatomical approach was associated with higher long-term success rate when compared to an approach without ICE. More recently Lin et al.33 reported an acute procedural success as high as 95% with ICE-guided catheter ablation, suggesting ablation as first-line therapy in the management of PM-VAs. In the current analysis the use of ICE to assist catheter stability, position and contact during ablation was related to similar acute procedural success (86.9%) as compared to not using ICE (90.1%), but long-term procedural success was better when ICE was used to assist ablation during the index procedure (74.2%) rather than ICE was not used (61.2%). Hence, in line with current guidelines on the management of VAs,2 our analysis suggest that ICE may be preferred to assist ablation in order to increase procedural outcomes.

Lesion size during RF catheter ablation is directly related to the contact of ablating electrode with the tissue. Theoretically, CFS
catheters may ensure lesion creation likely resulting in unexcitable areas. However, contrasting results on the effectiveness of CFS capability catheters for PM-VAs ablation have been reported. On the one hand, Rivera et al.\(^\text{32}\) reported that an approach based on the use of non-CFS catheters and cardiac computed tomography integration (CTII) into the electroanatomical mapping system was associated with an increase risk of recurrence of clinical arrhythmia at long-term follow-up as compared to ICE-guided ablation performed with CFS catheters (48% vs. 7%). On the other hand, Lin et al.\(^\text{33}\) did not find any difference between CFS group and non-CFS group neither in acute success (94% vs. 95%, \(p = .79\)) nor in clinical success during follow-up (84% vs. 78%, \(p = .41\)). Pooling data from different observational studies, our analysis showed that the use of catheters with CFS capability was related to higher percentages of freedom from arrhythmia recurrence (74.8%) as compared to non-CFS catheters (66.4%).

Nowadays, irrigated catheters are used worldwide because catheter irrigation allows greater power deliveries and creation of larger lesions by reducing tip-tissue interface temperature and charring formation. This aspect is crucial when approaching to PM-VA ablation because of the thickness of PMs and the frequent location of the focus deep inside the myocardium of PM base. Yamada et al.\(^\text{17}\) reported that the use of 4-tip non-irrigated catheters was associated with 100% rate of recurrence during long-term follow-up, and Yokokawa et al.\(^\text{16}\) found that failed ablation procedures were more common in patients with larger PMs mass, likely with an arrhythmogenic focus located away from the endocardial surface and hardly reachable regardless the use of irrigated catheters. Our analysis suggests that, although the acute success seems not to be affected by catheter irritation status, long-term arrhythmia-free survival is numerically higher when using an irrigated catheter (75%) rather than a non-irrigated catheter (58.7%).

In consideration of the poor ablation outcomes obtained by targeting the earliest activation site, some Authors proposed an ablation strategy based on global pace-mapping of preferential conduction exits and/or the ablation all around the PMs eliminating all the endocardial exits near the PM base, thus isolating the arrhythmogenic focus.\(^\text{23-24,30,32}\) In our analysis, this approach was associated with an acute success rate of 94.5%, but the success rate decreased at 72.4% at long-term follow-up. The large decrease in long-term as compared to the acute procedural results of this approach may be related to inadequate size and deepness of RF lesions, or to the presence of anatomical connections among PM body and left ventricular wall, relatively far from PM base. Indeed, Rivera et al.\(^\text{34}\) recently described prevalence and clinical significance of PM connections (PMCs), detected at cardiac magnetic resonance (CMR) in patients undergone PM ablation. The prevalence of PMCs among patients experiencing arrhythmia recurrences was as high as 91%, suggesting that preferential conduction through either the PM base or PMCs may exist and may contribute to recurrences at follow-up. This finding underlines the need of anatomy understanding focusing RF deliveries in discrete zones potentially responsible of arrhythmia recurrences at long-term follow-up.

Maintaining catheter contact and stability is challenging during RF deliveries. To overcome this issue, current guidelines on catheter ablation of VAs suggest the use of cryoablation to achieve stable contact during energy deliveries and improve procedure outcomes. Unfortunately, formal efficacy comparison between radiofrequency energy and cryoenergy has never been performed for PM-VAs so far. Yokokawa et al.\(^\text{16}\) reported the use of cryoablation for two PM-VAs and of RF energy for 40 PM-VAs, without reporting the outcomes for the different energy sources. Rivera et al.\(^\text{32}\) reported similar acute and long-term success rates when using cryoablation guided by CTII and ICE-guided CFS RF ablation, although 100% of patients undergone cryoablation achieved catheter stability versus 50% of patients undergone CFS RF energy ablation. Moreover, the use of cryo-catheter was not associated with proarrhythmic effects, whereas 78% of patients treated with RF energy developed catheter-induced arrhythmias (regardless CFS capability), further reducing catheter contact during RF energy delivery. Finally, Gordon et al.\(^\text{12}\) published a case series of 16 patients with failed RF ablation of PM-VAs in whom ablation strategy was intraoperatorally switched to cryoablation. Acute and long-term success rates were 93.8% (15/16), whereas in one patient the procedure was precluded by the development of acute aortic dissection while advancing the cryo-catheter in a retroaortic fashion to access the left ventricle. Overall, cryo-ablation seems an effective strategy to overcome stability and contact issues frequently encountered during RF ablation. However, some limitations of cryo-ablation

---

**TABLE 4** Subgroups analyses

|                          | Acute success rate | Long-term success rate |
|--------------------------|--------------------|------------------------|
| Presence of cardiomyopathy | 86.4%, 95% CI 79.7%–91.1%, \(p < .001, 12\%\) | N.A.                  |
| Absence of cardiomyopathy | 95.1%, 95% CI 87.6%–98.1%, \(p < .001, 12\%\) | N.A.                  |
| All ICE-guided procedure  | 86.9%, 95% CI 79.3%–92%, \(p < .001, 12\%\) | 74.2%, 95% CI 65.5%–81.3%, \(p < .001, 12\%\) |
| Not all ICE-guided procedure | 90.1%, 95% CI 82.2%–94.7%, \(p < .001, 12\%\) | 61.2%, 95% CI 45.8%–74.6%, \(p = .153, 12\%\) |
| Irrigated ablation catheter | 87%, 95% CI 80.3%–91.7%, \(p < .001, 12\%\) | 75%, 95% CI 68.8%–80.3%, \(p < .001, 12\%\) |
| Non-irrigated ablation catheter | 91.1%, 95% CI 79.8%–96.4%, \(p < .001, 12\%\) | 58.7%, 95% CI 41.5%–74%, \(p = .32, 12\%\) |
| CFS ablation catheter | 87.6%, 95% CI 76.3%–93.9%, \(p < .001, 12\%\) | 74.8%, 95% CI 61.4%–84.7%, \(p = .001, 12\%\) |
| Non-CFS ablation catheter | 83.8%, 95% CI 77%–89%, \(p < .001, 12\%\) | 66.4%, 95% CI 54.3%–76.7%, \(p = .009, 12\%\) |

Abbreviations: CI, confidence interval; CFS, contact force sensing; ICE, intracardiac echocardiography; NA, non available.
should be mentioned: cryo-catheter may be more difficult to manipulate as compared to RF catheters due to its unidirectional steering ability and stiffness that may expose to aortic complications when advancing in a retroaortic fashion without the use of a long sheath. Hence, the decision to use cryo-ablation should be guided by local expertise and physicians’ preference.

Evidence on RVPM VA ablation is scarce in literature. In our report, RVPM VAs represented only 4.3% of all PM VAs included in the analysis (25 out 584). Five studies reported the outcome of RVPM VAs ablation, and among them 1 out 5 specifically included patients suffering from RVPM VAs. 16,19–21,26 The acute procedural success of RVPM VAs ablation was 100%, whereas only one study reported the long-term outcome of RVPM VAs ablation. Due to the paucity of data, any specific analysis on RVPM VAs ablation is impossible and no formal comparison with LVPM VAs could be carried out. Available, limited data suggested that the ablation of RVPM VAs, due to the different thickness, mobility and anatomical complexity of RVPM, may be less challenging as compared to LVPM VAs. 16,19–21,28 New evidences are awaited to shed light on the peculiarity and outcomes of RVPM VAs ablation.

## 4.1 Study limitations

Although this is the first systematic review on PM-VAs ablation so far, several limitations should be considered. First, the included studies have an observational case series design, mainly retrospective, single-centered and based on small cohorts. Due to the case series design of the available studies, an analysis event versus nonevents was not possible, thus hampering the strength of the study. Drawing solid conclusions from our analysis is impossible in the absence of comparative data on outcomes using different ablation strategies and technologies. Moreover, the majority of the included studies describe the results and the experiences of tertiary referral EP centers, possibly leading to an erroneous estimation of cardiomyopathy prevalence across the study population.

## 5 CONCLUSIONS

Catheter ablation is an effective and safe strategy for PM-VAs, with an acute success rate of 88.1%, a long-term success rate of 69.2%, with a relatively low procedural complication rate of 1.7%. Data derived from low quality observational case-series studies show that the use of ICE, irrigated catheters and catheters with CFS capability are associated with higher rates of long-term procedural success of PM-VAs ablation.

## ACKNOWLEDGMENTS

This research did not receive any specific grant from founding agencies in the public, commercial, or not-for-profit sectors.

Open access funding provided by Universita degli Studi di Roma La Sapienza Universitawithin the CRUI-CARE Agreement.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## ORCID

Marco Valerio Mariani MD https://orcid.org/0000-0002-9480-1209
Andrea Natale MD https://orcid.org/0000-0002-5487-0728

## REFERENCES

1. Lavalle C, Mariani MV, Piro A, et al. Electrocardiographic features, mapping and ablation of idiopathic outflow tract ventricular arrhythmias. J Interv Card Electrophysiol. 2020;57:207-218.
2. Cronin EM, Bogun FM, Maury P, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Heart Rhythm. 2020;17:e2-e154.
3. Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clin Electrophysiol. 2015;1:116-123.
4. Enriquez A, Supple GE, Marchlinski FE, Garcia FC. How to map and ablate papillary muscle ventricular arrhythmias. Heart Rhythm. 2017;14:1721-1728.
5. Rivera S, Ricapito Mde L, Tomas L, et al. Results of cryoenergy and radiofrequency-based catheter ablation for treating ventricular arrhythmias arising from the papillary muscles of the left ventricle, guided by intracardiac echocardiography and image integration. Circ Arrhythm Electrophysiol. 2016;9:e003874.
6. Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg. 2011;39:91-92.
7. National Heart LaBI. Quality Assessment Tool for Case Series Studies. National Heart LaBI; https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/case_series
8. Rivera S, Ricapito MP, Espinoza J, et al. Cryoablation for ventricular arrhythmias arising from the papillary muscles of the left ventricle guided by intracardiac echocardiography and image integration. J Am Coll Cardiol EP. 2015;1:509-516.
9. Good E, Desjardins B, Jongnarangsin K, et al. Ventricular arrhythmias originating from a papillary muscle in patients without prior infarction: a comparison with fascicular arrhythmias. Heart Rhythm. 2008;5:1530-1537.
10. Crawford T, Mueller G, Good E, et al. Ventricular arrhythmias originating from papillary muscles in the right ventricle. Heart Rhythm. 2010;7:725-730.
11. Bogun F, Desjardins B, Crawford T, et al. Post-infarction ventricular arrhythmias originating in papillary muscles. *J Am Coll Cardiol.* 2008;51:1794-1802.

12. Gordon JP, Liang JJ, Pathak RK, et al. Percutaneous cryoablation for papillary muscle ventricular arrhythmias after failed radiofrequency catheter ablation. *J Cardiovasc Electrophysiol.* 2018;29:1654-1663.

13. Doppalapudi H, Yamada T, McElderry HT, Plumb VJ, Epstein AE, Kay GN. Ventricular tachycardia originating from the posterior papillary muscle in the left ventricle: a distinct clinical syndrome. *Circ Arrhythm Electrophysiol.* 2008;1:23-29.

14. Yamada T, McElderry HT, Okada T, et al. Idiopathic focal ventricular arrhythmias originating from the anterior papillary muscle in the left ventricle. *J Cardiovasc Electrophysiol.* 2009;20:866-872.

15. Abouezzeddine Q, Suleiman M, Buescher T, et al. Relevance of endocavitary structures in ablation procedures for ventricular tachycardia. *J Cardiovasc Electrophysiol.* 2010;21:245-254.

16. Yokokawa M, Good E, Desjardins B, et al. Predictors of successful catheter ablation of ventricular arrhythmias arising from the papillary muscles. *Heart Rhythm.* 2010;7:1654-1659.

17. Yamada T, Doppalapudi H, McElderry HT, et al. Idiopathic ventricular arrhythmias originating from the papillary muscles in the left ventricle: prevalence, electrocardiographic and electrophysiological characteristics, and results of the radiofrequency catheter ablation. *J Cardiovasc Electrophysiol.* 2010;21:62-69.

18. Ban JE, Lee HS, Lee DI, et al. Electrophysiological characteristics related to outcome after catheter ablation of idiopathic ventricular arrhythmia originating from the papillary muscle in the left ventricle. *Korean Circ J.* 2013;43:811-818.

19. Santoro F, Di Biase L, Hranitzky P, et al. Ventricular fibrillation triggered by PVCs from papillary muscles: clinical features and ablation. *J Cardiovasc Electrophysiol.* 2014;25:1159-1164.

20. Santoro F, Di Biase L, Hranitzky P, et al. Ventricular tachycardia originating from the septal papillary muscle of the right ventricle: electrocardiographic and electrophysiological characteristics. *J Cardiovasc Electrophysiol.* 2015;26:145-150.

21. Van Herendael H, Zado ES, Haqqani H, et al. Catheter ablation of ventricular fibrillation: importance of left ventricular outflow tract and papillary muscle triggers. *Heart Rhythm.* 2014;11:566-573.

22. Al’Aref SJ, Ip JE, Markowitz SM, et al. Differentiation of papillary muscle from fascicular and mitral annular ventricular arrhythmias in patients with and without structural heart disease. *Circ Arrhythm Electrophysiol.* 2015;8:616-624.

23. Chang YT, Lin YJ, Chung FP, et al. Ablation of ventricular arrhythmia originating at the papillary muscle using an automatic pacemapping module. *Heart Rhythm.* 2016;13:1431-1440.

24. Wo HT, Liao FC, Chang PC, et al. Circumferential ablation at the base of the left ventricular papillary muscles: a highly effective approach for ventricular arrhythmias originating from the papillary muscles. *Int J Cardiol.* 2016;220:876-882.

25. Peichl P, Baran J, Wichterle D, et al. The tip of the muscle is a dominant location of ventricular ectopy originating from papillary muscles in the left ventricle. *J Cardiovasc Electrophysiol.* 2018;29:64-70.

26. Proietti R, Rivera S, Dussault C, et al. Intracardiac echo-facilitated 3D electroanatomical mapping of ventricular arrhythmias from the papillary muscles: assessing the ‘fourth dimension’ during ablation. *Europace.* 2017;19:21-28.

27. Lee A, Hamilton-Craig C, Denman R, Haqqani HM. Catheter ablation of papillary muscle arrhythmias: implications of mitral valve prolapse and systolic dysfunction. *Pacing Clin Electrophysiol.* 2018;41:750-758.

28. Bassil G, Liu CF, Markowitz SM, et al. Comparison of robotic magnetic navigation-guided and manual catheter ablation of ventricular arrhythmias arising from the papillary muscles. *Europace.* 2018;20:ii5-ii10.

29. Li S, Wang Z, Shan Z, et al. Surface electrocardiography characteristics and radiofrequency catheter ablation of idiopathic ventricular arrhythmias originating from the left infero-septal papillary muscles: differences from those originating from the left posterior fascicle. *Europace.* 2018;20:1028-1034.

30. Itoh T, Yamada T. Usefulness of pace mapping in catheter ablation of left ventricular papillary muscle ventricular arrhythmias with a preferential conduction. *J Cardiovasc Electrophysiol.* 2018;29:889-899.

31. Enriquez A, Shirai Y, Huang J, et al. Papillary muscle ventricular arrhythmias in patients with arrhythmic mitral valve prolapse: electrophysiologic substrate and catheter ablation outcomes. *J Cardiovasc Electrophysiol.* 2019;30:827-835.

32. Rivera S, Tomas L, Ricapito MP, et al. Updated results on catheter ablation of ventricular arrhythmias arising from the papillary muscles of the left ventricle. *J Arrhythm.* 2019;35:99-108.

33. Lin AN, Shirai Y, Liang JJ, et al. Strategies for catheter ablation of left ventricular papillary muscle arrhythmias. An institutional experience. *J Am Coll Cardiol EP.* 2020;6:1381-1392.

34. Rivera S, Vecchio N, Ricapito P. Anatomical connections between the papillary muscles and the ventricular myocardium: correlation with QRS variability of ventricular arrhythmias. *Circ Arrhythm Electrophysiol.* 2019;12:e007004.

35. Della Rocca DG, Santini L, Forleo GB, et al. Novel perspectives on arrhythmia-induced cardiomyopathy: pathophysiology, clinical manifestations and an update on invasive management strategies. *Cardiol Rev.* 2015;23:135-141.

How to cite this article: Mariani MV, Piro A, Magnocavallo M, et al. Catheter ablation for papillary muscle arrhythmias: A systematic review. *Pacing Clin Electrophysiol.* 2022;45:519–531. https://doi.org/10.1111/pace.14462